Taken together, these strategies of using 177Lu-labeled chemotherapeutic drug-loaded nanosystems with BBN peptides for combined targeted therapy have shown promise in their application to GRPR-positive breast cancers. The gene discussed is GRPR; the disease is breast cancer.